Cohort demography and clinical features at baseline
| Overall (n=2196) | MEH (n=1929) | UHB (n=267) | |
| A | |||
| Sex n (%) | |||
| Female | 1350 (61.5) | 1167 (60.5) | 183 (68.5) |
| Male | 846 (38.5) | 762 (39.5) | 84 (31.5) |
| Age (years) n (%) | |||
| <65 | 133 (6.1) | 125 (6.5) | 8 (3.0) |
| 65–69 | 154 (7.0) | 139 (7.2) | 15 (5.6) |
| 70–74 | 312 (14.2) | 271 (14.0) | 41 (15.4) |
| 75–79 | 407 (18.5) | 369 (19.1) | 38 (14.2) |
| 80–84 | 515 (23.5) | 447 (23.2) | 68 (25.5) |
| 85+ | 675 (30.7) | 578 (30.0) | 97 (36.3) |
| Ethnicity n (%) | |||
| White | 1104 (50.3) | 905 (46.9) | 199 (74.5) |
| Not white | 959 (43.7) | 945 (49.0) | 14 (5.2) |
| Not reported | 133 (6.1) | 79 (4.1) | 54 (20.2) |
| Smoking status n (%) | |||
| Yes | 149 (6.8) | 140 (7.3) | 9 (3.4) |
| B | |||
| Visual acuity (VA) ETDRS letters | |||
| Mean (SD) | 55.4 (16.8) | 55.9 (16.3) | 51.7 (20.0) |
| Median (min, max) | 59.0 (0, 94.0) | 60.0 (0, 90.0) | 55.0 (0, 94.0) |
| VA ≥70 n (%) | |||
| Yes | 563 (25.6) | 503 (26.1) | 60 (22.5) |
| No | 1633 (74.4) | 1426 (73.9) | 207 (77.5%) |
| VA ≤20 n (%) | |||
| Yes | 55 (2.5) | 40 (2.1) | 15 (5.6) |
| No | 2141 (97.5) | 1889 (97.9) | 252 (94.4) |
| VA <25 n (%) | |||
| Yes | 139 (6.3) | 112 (5.8) | 27 (10.1) |
| No | 2057 (93.7) | 1817 (94.2) | 240 (89.9) |
| No or unknown | 2047 (93.2) | 1789 (92.7) | 258 (96.6) |
Mean, SD and distribution are shown for (A) demography (sex, ethnicity, smoking status and age) and (B) visual parameters in approximate ETDRS letters of patients with nAMD at initiation of anti-VEGF therapy at MEH and UHB.
MEH, Moorfields Eye Hospital; nAMD, neovascular age-related macular degeneration; UHB, University Hospitals Birmingham; VEGF, vascular endothelial growth factor.